Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The Biden administration wants to expand access to popular weight loss drugs like Wegovy and Ozempic. The new proposal would ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Jordan welcomed a ceasefire that entered into force Wednesday between Israel and Hezbollah in Lebanon, calling it a critical step towards ending the war between Israel and Hamas in Gaza.

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Shares of Amgen Inc. ($AMGN) edged down 0.3% in premarket trading Wednesday, on course to extend a losing streak to a third ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting ...

The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and $11 billion for Medicaid over a decade. Total Medicare drug spending over ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...